Rhesus monkeys: Oral absorption of Navuridine (AzddU) was virtually complete after 60 mg/kg. However, bioavailability of both nucleosides was markedly lower (less than 50%) after 200 mg/kg. Young adult male rhesus monkeys weighing 5-6 kg were used for all intravenous and oral studies. Each monkey received a single dose of AzddU or AZT. AzddU, 60 mg/kg, was administered intravenously (20 ml) as a bolus to three monkeys (563D, AP21, and RJN2) and 60 mg/kg AZT was similarly administered to one monkey (N785). For oral bioavailability studies, each of two monkeys received 60 mg/kg (AP19 and RKOl) or 200 mg/kg (634D and N854) AzddU in 50 ml water by gastric intubation. One monkey received 60 mg/kg (RFL1) AZT orally and two monkeys were given 200 mg/kg (231D and AP17) AZT orally.

Navuridine (AzddU) inhibited HIV-1 replication in human peripheral blood mononuclear (PBM) cells in the 0.18 to 0.46 uM range.